IP Verse

Fc Region-Containing Polypeptides That Exhibit Improved Effector Function Due To Alterations Of The Extent Of Fucosylation, And Methods For Their Use - EP2486141

The patent EP2486141 was granted to Macrogenics on Jan 10, 2018. The application was originally filed on Oct 7, 2010 under application number EP10822699A. The patent is currently recorded with a legal status of "Revoked".

EP2486141

MACROGENICS
Application Number
EP10822699A
Filing Date
Oct 7, 2010
Status
Revoked
Jul 16, 2021
Grant Date
Jan 10, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PATENTANWALTE ISENBRUCK BOSL HORSCHLER PARTG MBBOct 10, 2018-ADMISSIBLE
STRAWMANOct 10, 2018VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE

Patent Citations (182) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20020113929-
DESCRIPTIONUS20020277370-
DESCRIPTIONUS20020403266-
DESCRIPTIONUS20030439498-
DESCRIPTIONUS20030439709-
DESCRIPTIONUS20030456041-
DESCRIPTIONUS20030643857-
DESCRIPTIONUS20040562804-
DESCRIPTIONUS20040569882-
DESCRIPTIONUS20040582043-
DESCRIPTIONUS20040582044-
DESCRIPTIONUS20040582045-
DESCRIPTIONUS20040636663-
DESCRIPTIONUS20050271140-
DESCRIPTIONUS20050305787-
DESCRIPTIONUS20050524134-
DESCRIPTIONUS20050697805-
DESCRIPTIONUS20060809116-
DESCRIPTIONUS20060816126-
DESCRIPTIONUS20060816688-
DESCRIPTIONEP0003089
DESCRIPTIONEP0239400
DESCRIPTIONEP0359096
DESCRIPTIONEP0413622
DESCRIPTIONEP0519596
DESCRIPTIONEP0592106
DESCRIPTIONEP0598877
DESCRIPTIONEP1229125
DESCRIPTIONUS2002028486
DESCRIPTIONUS2003115614
DESCRIPTIONUS2003229208
DESCRIPTIONUS2004049014
DESCRIPTIONUS2004185045
DESCRIPTIONUS2005037000
DESCRIPTIONUS2005054832
DESCRIPTIONUS2005064514
DESCRIPTIONUS2005215767
DESCRIPTIONUS2005260213
DESCRIPTIONUS2006013810
DESCRIPTIONUS2008044417
DESCRIPTIONUS4444887
DESCRIPTIONUS4474893
DESCRIPTIONUS4526938
DESCRIPTIONUS4676980
DESCRIPTIONUS4714681
DESCRIPTIONUS4716111
DESCRIPTIONUS4741900
DESCRIPTIONUS4816397
DESCRIPTIONUS4816567
DESCRIPTIONUS4880078
DESCRIPTIONUS4925648
DESCRIPTIONUS4980286
DESCRIPTIONUS5128326
DESCRIPTIONUS5166057
DESCRIPTIONUS5225539
DESCRIPTIONUS5290540
DESCRIPTIONUS5322798
DESCRIPTIONUS5341215
DESCRIPTIONUS5413923
DESCRIPTIONUS5530101
DESCRIPTIONUS5545806
DESCRIPTIONUS5565332
DESCRIPTIONUS5569825
DESCRIPTIONUS5573920
DESCRIPTIONUS5585089
DESCRIPTIONUS5601819
DESCRIPTIONUS5605793
DESCRIPTIONUS5624821
DESCRIPTIONUS5625126
DESCRIPTIONUS5633425
DESCRIPTIONUS5661016
DESCRIPTIONUS5677171
DESCRIPTIONUS5679377
DESCRIPTIONUS5693761
DESCRIPTIONUS5693762
DESCRIPTIONUS5807715
DESCRIPTIONUS5811238
DESCRIPTIONUS5814318
DESCRIPTIONUS5830721
DESCRIPTIONUS5834252
DESCRIPTIONUS5837458
DESCRIPTIONUS5855913
DESCRIPTIONUS5874064
DESCRIPTIONUS5877396
DESCRIPTIONUS5877397
DESCRIPTIONUS5885573
DESCRIPTIONUS5885793
DESCRIPTIONUS5888533
DESCRIPTIONUS5912015
DESCRIPTIONUS5916597
DESCRIPTIONUS5916771
DESCRIPTIONUS5934272
DESCRIPTIONUS5939598
DESCRIPTIONUS5945155
DESCRIPTIONUS5985309
DESCRIPTIONUS5985320
DESCRIPTIONUS5989463
DESCRIPTIONUS6019968
DESCRIPTIONUS6180370
DESCRIPTIONUS6194551
DESCRIPTIONUS6218149
DESCRIPTIONUS6268125
DESCRIPTIONUS6277375
DESCRIPTIONUS6289286
DESCRIPTIONUS6373577
DESCRIPTIONUS6472511
DESCRIPTIONUS6602684
DESCRIPTIONUS6676927
DESCRIPTIONUS7276586
DESCRIPTIONUS7317091
DESCRIPTIONWO0042072
DESCRIPTIONWO0061739
DESCRIPTIONWO0100245
DESCRIPTIONWO0129246
DESCRIPTIONWO0177137
DESCRIPTIONWO0230954
DESCRIPTIONWO0231140
DESCRIPTIONWO03035835
DESCRIPTIONWO2004063351
DESCRIPTIONWO2005110474
DESCRIPTIONWO2005115452
DESCRIPTIONWO2007041635
DESCRIPTIONWO2009016164
DESCRIPTIONWO9100360
DESCRIPTIONWO9105548
DESCRIPTIONWO9109967
DESCRIPTIONWO9110741
DESCRIPTIONWO9201047
DESCRIPTIONWO9205793
DESCRIPTIONWO9208802
DESCRIPTIONWO9219244
DESCRIPTIONWO9220373
DESCRIPTIONWO9308829
DESCRIPTIONWO9315199
DESCRIPTIONWO9315200
DESCRIPTIONWO9317715
DESCRIPTIONWO9404690
DESCRIPTIONWO9620698
DESCRIPTIONWO9627011
DESCRIPTIONWO9633735
DESCRIPTIONWO9634096
DESCRIPTIONWO9732572
DESCRIPTIONWO9733899
DESCRIPTIONWO9734631
DESCRIPTIONWO9734911
DESCRIPTIONWO9744013
DESCRIPTIONWO9816654
DESCRIPTIONWO9823289
DESCRIPTIONWO9824893
DESCRIPTIONWO9831346
DESCRIPTIONWO9846645
DESCRIPTIONWO9850433
DESCRIPTIONWO9915154
DESCRIPTIONWO9920253
DESCRIPTIONWO9923105
DESCRIPTIONWO9958572
DESCRIPTIONWO9966903
EXAMINATIONWO2007041635
INTERNATIONAL-SEARCH-REPORTUS2008161541
INTERNATIONAL-SEARCH-REPORTUS2009010921
INTERNATIONAL-SEARCH-REPORTUS2009076251
INTERNATIONAL-SEARCH-REPORTUS2009208500
OPPOSITIONEP1176195
OPPOSITIONUS2004132101
OPPOSITIONUS2005054832
OPPOSITIONUS2006024298
OPPOSITIONUS2008138349
OPPOSITIONUS2008206867
OPPOSITIONUS5624821
OPPOSITIONUS5648260
OPPOSITIONWO0158957
OPPOSITIONWO2004029207
OPPOSITIONWO2004099249
OPPOSITIONWO2005040217
OPPOSITIONWO2007008943
OPPOSITIONWO2007041635
OPPOSITIONWO2008036688
OPPOSITIONWO2008114011
OPPOSITIONWO2008137382
OPPOSITIONWO2011044368
SEARCHUS2005054832
SEARCHWO2009016164

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- CHAPPEL M S; ET AL, "Identification of a secondary FcyRI binding site within a genetically engineered human IgG antibody", Journal of Biological Chemistry, (19930000), vol. 268, no. 33, pages 25124 - 25131, XP002337952-
OPPOSITION- LUND J; ET AL, "Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains", Journal of Immunology, (19961200), vol. 157, no. 11, pages 4963 - 4969, XP002484003-
OPPOSITION- JASSAL, RAMESH et al., "Sialylation of human IgG-Fc 2001 carbohydrate by transfected rat a2, 6-sialyltransferase", Biochemical and biophysical research communications, (20010817), vol. 286, no. 2, pages 243 - 249, XP002574380
OPPOSITION- SCANLAN CHRISTOPHER N; BURTON D R; DWEK R A, "Making autoantibodies safe", PNAS, (20080314), vol. 105, no. 11, pages 4081 - 4082, XP002569096
OPPOSITION- HOSSLER et al., "Optimal and consistent protein glycosylation in mammalian cell culture", Glycobiology, (20090603), vol. 19, no. 9, pages 936 - 949, XP055112498
OPPOSITION- A. C. Vestrheim, A. Moen, W. Egge-Jacobsen, D. B. Bratlie, T. E. Michaelsen, "Different Glycosylation Pattern of Human lgG 1 and lgG3 Antibodies Isolated from Transiently as well as Permanently Transfected Cell Lines", Scandinavian Journal of Immunology, (20130500), vol. 77, no. 5, pages 419 - 428, XP055523377
OPPOSITION- STAVENHAGEN, JEFFREY B. et al., "Fc optimization of 2007 therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor ex pansion in vivo via low-affinity activating Fcy receptors", Cancer research, (20070901), vol. 67, no. 18, pages 8882 - 8890, XP002489883
OPPOSITION- STAVENHAGEN JEFFREY B; ET AL, "Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fc gamma receptors", Cancer Research, (20070900), vol. 67, no. 18, pages 8882 - 8890, XP002489883
OPPOSITION- RANKIN , CHRISTOPHER T. et al., "CD 32B, the human 2006 inhibitory Fc-y receptor IIB, as a target for monoclonal antibody therapy of B- cell lymphoma", Blood, (20061000), vol. 108, no. 7, pages 2384 - 2391, XP002522503
OPPOSITION- VOYNOV, VLADIMIR et al., "Dynamic fluctuations of protein- carbohydrate interactions promote protein aggregation", PLoS One, (20091200), vol. 4, no. 12, pages e8425-1 - e8425-10, XP055523337
SEARCH- KANDA YUTAKA ET AL, "Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, (20060929), vol. 17, no. 1, doi:10.1093/GLYCOB/CWL057, ISSN 0959-6658, pages 104 - 118, XP002443679 [A] 1-17 * the whole document *
SEARCH- STAVENHAGEN JEFFREY B ET AL, Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fc gamma receptors, CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, PAGE(S) 8882 - 8890, (20070901), ISSN 0008-5472, XP002489883 [X] 1-17 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents